Vivoflora

Vivoflora is a clinical-stage biotechnology company focused on developing precision microbiome-based therapeutics, specifically Live Biotherapeutic Products (LBPs). The company leverages the unique properties of Bifidobacterium infantis to restore gut health and modulate the immune system, particularly in infants and young children. Their lead programs target conditions such as atopic dermatitis and food allergies by addressing the underlying microbial dysbiosis. Founded by Dr. David Kyle, a pioneer in the field of nutritional biotechnology, Vivoflora utilizes a proprietary platform to identify and deliver specific microbial strains that provide long-term health benefits. The company's research is deeply rooted in the science of human milk and its role in shaping the early-life microbiome.